| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.8 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.8 |